Quality of Life Research

, Volume 25, Issue 1, pp 201–211 | Cite as

Health-related quality of life in patients with prominent negative symptoms: results from a multicenter randomized Phase II trial on bitopertin

  • Diana Rofail
  • Antoine Regnault
  • Stéphanie le Scouiller
  • Carmen Galani Berardo
  • Daniel Umbricht
  • Ray Fitzpatrick



Symptoms of schizophrenia fall into three categories (positive, negative and cognitive symptoms), which probably impact differently on patient’s health-related quality of life (HRQoL). The present study aimed to explore HRQoL in patients with prominent negative symptoms.


In the 323 patients with prominent negative symptoms included in a multicenter Phase II trial investigating the safety and efficacy of bitopertin, HRQoL was assessed using the Schizophrenia Quality of Life Scale (SQLS), symptoms severity using the Positive and Negative Syndrome Scale and functioning using the Personal and Social Performance Scale. SQLS measurement properties were assessed; HRQoL was compared between treatment arms, and relationships between HRQoL, symptoms and functioning at baseline were explored.


Both SQLS scores (Vitality/Cognition and Psychosocial Feelings) demonstrated good test–retest (ICC = 0.77 and 0.74) and internal consistency reliability (Cronbach’s α = 0.86 and 0.93). Clinical validity with regard to schizophrenia severity and ability to detect change in severity of symptoms of schizophrenia were satisfactory. The SQLS structure was not formally disconfirmed. No statistically significant difference was observed between treatment arms. Negative symptoms were more strongly associated with functioning than positive symptoms. Functioning and Anxiety/Depression were strongly related to both SQLS domains.


Overall, SQLS measurement properties were supported in these patients with prominent negative symptoms of schizophrenia. The impact of negative symptoms on functioning and HRQoL suggests that improving these symptoms will be a meaningful benefit in this population of patients.


Quality of life Schizophrenia Negative symptoms Bitopertin 



The authors would like to thank Fatoumata Fofana (Mapi) for support with the statistical analysis, and Jérémy Lambert (Mapi) for medical writing assistance and editorial support in manuscript preparation. J&J agree and acknowledge that OXFORD OUTCOMES exclusively owns all intellectual and other property rights, including all worldwide copyrights to the SQLS and revisions to it for perpetuity. From 2003, OXFORD OUTCOMES is permitted to consent to the use of the SQLS or revisions of it by any person or entity subject to them signing the user’s agreement without the permission or knowledge of J&J.

Compliance with Ethical Standards


This study was funded by Hoffmann-La Roche.

Conflict of interest

DR and SS are employees of Roche Products LTD, and CGB and DU are employees of F Hoffmann-La Roche. AR, employee of Mapi, was paid consultant to Roche Products LTD. RF was paid consultant to Roche Products LTD.

Ethical standard

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, and Center for Devices and Radiological Health. (2009). Guidance for industry. Patient-reported outcome measures: Use in medical product development to support labeling claims.
  2. 2.
    McCabe, R., Saidi, M., & Priebe, S. (2007). Patient-reported outcomes in schizophrenia. British Journal of Psychiatry. Supplement, 50, s21–s28.CrossRefGoogle Scholar
  3. 3.
    Gee, L., Pearce, E., & Jackson, M. (2003). Quality of life in schizophrenia: A grounded theory approach. Health and Quality of Life Outcomes, 1, 31.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    van Os, J., & Kapur, S. (2009). Schizophrenia. Lancet, 374(9690), 635–645.PubMedCrossRefGoogle Scholar
  5. 5.
    Folsom, D. P., Depp, C., Palmer, B. W., Mausbach, B. T., Golshan, S., Fellows, I., et al. (2009). Physical and mental health-related quality of life among older people with schizophrenia. Schizophrenia Research, 108(1–3), 207–213.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Wilkinson, G., Hesdon, B., Wild, D., Cookson, R., Farina, C., Sharma, V., et al. (2000). Self-report quality of life measure for people with schizophrenia: The SQLS. British Journal of Psychiatry, 177(42–6), 42–46.PubMedCrossRefGoogle Scholar
  7. 7.
    Rouillon, F., Eriksson, L., Burba, B., Raboch, J., Kaprinis, G., & Schreiner, A. (2013). Functional recovery results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Acta Neuropsychiatrica, 25(5), 297–306.PubMedCrossRefGoogle Scholar
  8. 8.
    Mortimer, A. M., & Al-Agib, A. O. (2007). Quality of life in schizophrenia on conventional versus atypical antipsychotic medication: A comparative cross-sectional study. International Journal of Social Psychiatry, 53(2), 99–107.PubMedCrossRefGoogle Scholar
  9. 9.
    Shirazi-Southall, S., Rodriguez, D. E., & Nomikos, G. G. (2002). Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology, 26(5), 583–594.PubMedCrossRefGoogle Scholar
  10. 10.
    Hill, S. K., Bishop, J. R., Palumbo, D., & Sweeney, J. A. (2010). Effect of second-generation antipsychotics on cognition: Current issues and future challenges. Expert Review of Neurotherapeutics, 10(1), 43–57.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet, 373(9657), 31–41.PubMedCrossRefGoogle Scholar
  12. 12.
    Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010). Schizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and future. Schizophrenia Research, 122(1–3), 1–23.PubMedCrossRefGoogle Scholar
  13. 13.
    Malhotra, A. K., Pinals, D. A., Weingartner, H., Sirocco, K., Missar, C. D., Pickar, D., et al. (1996). NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology, 14(5), 301–307.PubMedCrossRefGoogle Scholar
  14. 14.
    Noetzel, M. J., Jones, C. K., & Conn, P. J. (2012). Emerging approaches for treatment of schizophrenia: Modulation of glutamatergic signaling. Discovery of Medicine, 14(78), 335–343.Google Scholar
  15. 15.
    Pinard, E., Alanine, A., Alberati, D., Bender, M., Borroni, E., Bourdeaux, P., et al. (2010). Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. Journal of Medicinal Chemistry, 53(12), 4603–4614.PubMedCrossRefGoogle Scholar
  16. 16.
    Umbricht, D., Alberati, D., Martin-Facklam, M., Borroni, E., Youssef, E. A., Ostland, M., et al. (2014). Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: A randomized, double-blind, proof-of-concept study. JAMA Psychiatry, 71(6), 637–646.PubMedCrossRefGoogle Scholar
  17. 17.
    Marder, S. R., Davis, J. M., & Chouinard, G. (1997). The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials. Journal of Clinical Psychiatry, 58(12), 538–546.PubMedCrossRefGoogle Scholar
  18. 18.
    Martin, C. R., & Allan, R. (2007). Factor structure of the Schizophrenia Quality of Life Scale Revision 4 (SQLS-R4). Psychology, Health and Medicine, 12(2), 126–134.PubMedCrossRefGoogle Scholar
  19. 19.
    Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–276.PubMedCrossRefGoogle Scholar
  20. 20.
    Patrick, D. L., Burns, T., Morosini, P., Rothman, M., Gagnon, D. D., Wild, D., et al. (2009). Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia. Current Medical Research and Opinion, 25(2), 325–338.PubMedCrossRefGoogle Scholar
  21. 21.
    Schumacker, R. E., & Lomax, R. G. (1996). A beginner’s guide to structural equation modeling. Mahwah, NJ: Lawrence Erlbaum Associates.Google Scholar
  22. 22.
    Chassany, O., Sagnier, P., Marquis, P., Fullerton, S., & Aaronson, N. (2002). Patient-reported outcomes: The example of health-related quality of life: A European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Information Journal, 36, 209–238.CrossRefGoogle Scholar
  23. 23.
    Zumbo, B. D. (1999). A handbook on the Theory and Methods of Differential Item Functioning (DIF): Logistic Regression Modeling as a Unitary Framework for Binary and Likert-type (Ordinal) Item Scores. Ottawa, ON: Directorate of Human Resources Research and Evaluation, Department of National Defense.Google Scholar
  24. 24.
    Gelin, M. N., & Zumbo, B. D. (2003). Differential Item Functioning results may change depending on how an item is scored: an illustration with the Center for Epidemiologic Studies Depression Scale. Educational and Psychological Measurement, 63(1), 65–74.CrossRefGoogle Scholar
  25. 25.
    Jodoin, M. G., & Gierl, M. J. (2001). Evaluating Type I error and power rates using an effect size measure with the logistic regression procedure for DIF detection. Applied Measurement in Education, 14, 329–349.CrossRefGoogle Scholar
  26. 26.
    Hays, R. D., Anderson, R. & Revicki, D. (1998). Assessing reliability and validity of measurement in clinical trials. In Quality of life assessment in clinical trials: Methods and practice (pp. 169–182). Oxford: Oxford University Press.Google Scholar
  27. 27.
    Nunnally, J. C., & Bernstein, I. H. (1994). Psychometric theory. New York: McGraw-Hill Inc.Google Scholar
  28. 28.
    Guyatt, G. H., Deyo, R. A., Charlson, M., Levine, M. N., & Mitchell, A. (1989). Responsiveness and validity in health status measurements: A clarification. Journal of Clinical Epidemiology, 42(5), 403–408.PubMedCrossRefGoogle Scholar
  29. 29.
    Cohen, J. (1977). Statistical power analysis for the behavioral sciences. New York: Academic Press.Google Scholar
  30. 30.
    Kline, R. B. (2005). Principle and practice of structural equation modeling. New York: Guilford Press.Google Scholar
  31. 31.
    Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA, 273(1), 59–65.PubMedCrossRefGoogle Scholar
  32. 32.
    Arango, C., Nasrallah, H., Lawrie, S., Ochi Lohmann, T., Zhu, J., Garibaldi, G., et al. (2013) Efficacy and safety of adjunctive bitopertin (5 and 10 mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics—Results from the Phase III DayLyte study. In 4th Biennial Schizophrenia International Research Society Conference, 5–9 April 2013. Florence, Italy.Google Scholar
  33. 33.
    Blaetter, T., Bugarski-Kirola, D., Fleischhacker, W. W., Bressan, R. A., Arango, C., Abi-Saab, D., et al. (2013). Efficacy and safety of adjunctive bitopertin (10 and 20 mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics—Results from the Phase III FlashLyte Study. In 4th Biennial Schizophrenia International Research Society Conference, 5–9 April 2013. Florence, Italy.Google Scholar
  34. 34.
    Taha, N. A., Ibrahim, M. I., Rahman, A. F., Shafie, A. A., & Rahman, A. H. (2012). Validation of the Schizophrenia Quality of Life Scale Revision 4 among Chronic Schizophrenia Patients in Malaysia. Value in Health Regional Issues, 1(1), 82–86.CrossRefGoogle Scholar
  35. 35.
    Wilkinson, G., Clayson, D., Wild, D., Doll, H., Martin, C., & De Hert, M. (2004) The development and psychometric validation of the Schizophrenia Quality of Life Scale-revision 4 (SQLS-R4). Abstracts of the XIIth Biennal Winter Workshop on Schizophrenia. Schizophrenia Research. July 2, 2004.Google Scholar
  36. 36.
    Galuppi, A., Turola, M. C., Nanni, M. G., Mazzoni, P., & Grassi, L. (2010). Schizophrenia and quality of life: How important are symptoms and functioning? International Journal of Mental Health Systems, 4, 31.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Lipkovich, I. A., Deberdt, W., Csernansky, J. G., Sabbe, B., Keefe, R. S., & Kollack-Walker, S. (2009). Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: A path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. BMC Psychiatry, 9, 44.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Rabinowitz, J., Levine, S. Z., Garibaldi, G., Bugarski-Kirola, D., Berardo, C. G., & Kapur, S. (2012). Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data. Schizophrenia Research, 137(1–3), 147–150.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Diana Rofail
    • 1
  • Antoine Regnault
    • 2
  • Stéphanie le Scouiller
    • 1
  • Carmen Galani Berardo
    • 3
  • Daniel Umbricht
    • 3
  • Ray Fitzpatrick
    • 4
  1. 1.Roche Products LTDWelwyn Garden CityUK
  2. 2.Mapi, HEOR & Strategic Market AccessLyonFrance
  3. 3.F Hoffmann – La RocheBaselSwitzerland
  4. 4.University of OxfordOxfordUK

Personalised recommendations